Showing 821-830 of 9712 results for "".
Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentSkin Cancer Prevention Through Photoprotection: What Your Patients Should Know
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-cancer-prevention-through-photoprotection-what-your-patients-should-know/26540/Skin Cancer Prevention Through Photoprotection: What Your Patients Should KnowThe Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Utilization of Sunscreen: An Interview with Dr. Murad Alam
https://practicaldermatology.com/topics/skin-cancer-photoprotection/utilization-of-sunscreen-an-interview-with-dr-murad-alam/26546/Utilization of Sunscreen: An Interview with Dr. Murad AlamLocks and Crocs: Keep on your Socks
https://practicaldermatology.com/youngmd-connect/resident-resource-center/locks-and-crocs-keep-on-your-socks/23454/A 44-year-old man develops new-onset recurrent hair splinters in both feet from lined Crocs.Characterizing “Obese Skin”: Aesthetic Considerations Following GLP-1-Induced Rapid Weight Loss
https://practicaldermatology.com/topics/cosmetic/characterizing-obese-skin/24565/Characterizing “Obese Skin”: Aesthetic Considerations Following GLP-1-Induced Rapid Weight LossTreatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Pharma Sales 2.0
https://practicaldermatology.com/topics/practice-management/pharma-sales-20/23959/A behind-the-scenes look at how ReachRX aims to transform pharma sales and boost patient access.Strategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.How Exceptional Reception Design Can Maximize Sales
https://practicaldermatology.com/topics/practice-management/how-exceptional-reception-design-can-maximize-sales/23779/Many factors determine the impact of this generally small but important space.